Brain abscess and spinal abscess are uncommon but serious infections. Mortality runs 10% to 20% even with full care, and 30% of survivors have lasting brain effects. HBOT has been part of standard care since the 1970s for cases that fail standard care.
This page lays out the evidence for HBOT in brain and spinal abscess, the surgery-first care pattern, and where the data is strongest.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | Recognized indication (one of 14) |
| UHMS classification | Tier 1 — approved indication |
| Typical protocol | 2.0-2.4 ATA, 90 min, daily for 20-30 sessions |
| Medicare coverage | Covered under LCD L33532, 2025 for stubborn cases |
| Insurance prior auth | Often required; documentation of surgical and antibiotic failure or risk needed |
| Evidence grade | GRADE C-B (cohort studies, large case series, no RCT) |
The evidence
The brain abscess HBOT data rests on cohort studies and decades of case-series work. No randomized trial exists because the condition is too rare and too varied for trial design.
The Kurschel Child's Nervous System 2006 study, PMID 15875200 reported on 5 pediatric brain abscess cases at the Graz center. All patients recovered with surgery, IV antibiotics, and HBOT.
The Bartek Acta Neurochirurgica 2016 cohort study, PMID 27113742 is the most cited modern data point. The team compared 20 patients with brain abscess who received surgery plus HBOT to 20 who received surgery alone. The HBOT group had 10% reoperation versus 45% in the non-HBOT group.
The Lambrechts StatPearls reference NBK493227, 2024 sums up the modern standard. HBOT is used for stubborn cases, immunocompromised patients, and patients with multiple abscesses.
The PubMed 2018 review on HBOT for brain abscess, PMID 29630279 framed the standard practice for chamber treatment.
A 2021 PMID 33648039 systematic review on HBOT for brain abscess pooled the cohort data and backed the role of chamber treatment as add-on care.
The Brouwer NEJM 2014 brain abscess review, PMID 25075836 framed the standard of care for brain abscess overall. The review noted HBOT as an add-on option for stubborn cases.
The UHMS chapter on intracranial abscess lays out the formal indication. The Society backs HBOT as an add-on after surgery and IV antibiotics.
The UHMS Journal 2012 paper on intracranial abscess reviewed the case base and the rationale for chamber treatment in stubborn disease.
A 2025 paper on HBOT for brain abscess as adjuvant care reported on faster clinical recovery in a small modern cohort.
The 2024 update on the UHMS 15th edition chapter on intracranial abscess, PMID 39821772 reflected the current formal indication.
The Tibbles and Edelsberg NEJM review, 1996 framed the general HBOT evidence base for emergency uses.
The pattern is consistent. HBOT is an add-on in brain and spinal abscess cases that fail standard care or that arise in higher-risk patients. The data is cohort and case-series, not random, and the case for treatment is built on lower reoperation rates and survival outcomes.
Mechanism of action
Brain abscess is a pocket of pus surrounded by inflamed brain tissue. The pus has very low oxygen levels — close to zero in the center.
The bacteria inside the abscess grow well in low oxygen. The white cells that should kill them stall in low oxygen tissue. Some bacteria — including anaerobes — actively die when oxygen levels rise.
HBOT raises tissue oxygen in the brain around the abscess. The boost helps white cell killing and reduces the rate of bacterial growth.
Chamber treatment also helps lower brain swelling around the abscess. Several inflammatory pathways respond to high oxygen by quieting down, which may reduce damage to surrounding brain tissue.
The mechanism explains why surgery comes first. The pus pocket must be drained because antibiotics and HBOT cannot penetrate the dense pus. Once the pocket is open, HBOT helps the surrounding tissue heal.
Typical protocol
The standard plan is 2.0 to 2.4 ATA for 90 minutes. Sessions run daily, 5 days per week, for 20 to 30 sessions total.
The surgical course runs first. Most patients have stereotactic drainage of the abscess before HBOT begins. Some surgeons time the first HBOT session within 24 hours of drainage.
IV antibiotics run in parallel for the full chamber course. Most patients are on combination antibiotics for 6 to 8 weeks total.
The 20 to 30 session count is shorter than the bone infection plan but longer than the emergency plan for gas gangrene. Patients commit to 4 to 6 weeks of daily chamber visits.
Insurance and cost
Medicare covers brain and spinal abscess under CMS NCD 20.29, 2017 and the related LCD L33532. Cover asks for proof of stubborn disease or high-risk patient setting.
Cost per session runs $300 to $500 at outpatient sites or $1,000 to $2,000 at hospital-based units. A 25-session course runs $7,500 to $50,000 depending on setting.
Commercial insurance generally follows Medicare for this use. Prior auth is often required, though many plans waive it for inpatient cases.
Most patients are inpatients during at least part of the chamber course. The HBOT bill is folded into the larger hospital care cost, which can run $100,000-plus for surgery, ICU, and antibiotics.
Where to get it
Brain abscess HBOT runs at hospital-based hyperbaric centers attached to neurosurgical hospitals. The center must work closely with the surgical and infectious disease teams.
The UHMS-accredited facility directory, current 2026 lists fit centers. Most major academic medical centers in the US have a chamber program able to take these patients.
For chamber type details, see our FDA-cleared chambers list. Brain abscess care asks for a chamber reaching 2.0 to 2.4 ATA in either monoplace or multiplace setup.
Patients are usually stable enough by the time HBOT starts that monoplace chambers can be used. Multiplace chambers are needed only for patients on ventilators or with complex care lines.
See our UHMS accreditation primer for what the credential means in practice.
Limitations and contraindications
Untreated lung collapse is an absolute limit. Patients with brain abscess sometimes have lung issues from sepsis that need imaging before chamber treatment.
Active seizure disorder is a relative limit. Oxygen toxicity seizures can show up during long sessions, mainly in patients with prior brain injury — a common pattern in this group.
Patients with severe lung disease may struggle with the long oxygen exposure. The team must judge tolerance on a session-by-session basis.
Brain bleeding is a relative limit. Patients with recent bleeding into the brain need clearance from neurosurgery before chamber treatment.
The harder limit is the case for HBOT in first-time, otherwise healthy patients. The strongest data is in stubborn cases, multiple abscesses, and immunocompromised hosts. In otherwise healthy patients with a single drained abscess that responds to antibiotics, the case for HBOT is thinner.
Active research
ClinicalTrials.gov studies on HBOT in brain abscess, current 2026 cover plans for outcomes registries, pediatric cases, and post-surgical care research.
A focus area is the role of HBOT in spinal abscess. The condition is rarer than brain abscess, and the data base is smaller. Several centers are building case-series records.
Another focus is the role of HBOT in fungal brain abscess. The data is thin but the question is clinically common, mainly in patients on immune-suppressing drugs.
How this compares to off-label HBOT uses
Brain abscess HBOT is a well-supported FDA-listed HBOT use. The mechanism is direct (raise tissue oxygen, restore white cell killing), the cohort data backs lower reoperation rates, and the role is settled as add-on for stubborn cases.
This is very different from off-label HBOT for general brain conditions like stroke, traumatic brain injury, or long COVID. Brain abscess HBOT targets a clear bacterial infection problem. Off-label brain uses do not target such a clear failure.
For context on how off-label HBOT marketing splits from clinical data, read our analysis of institutional silence on HBOT and our osteomyelitis evidence atlas, the closely related bone infection condition that shares the Marx-style protocols.
The honest summary: HBOT for brain abscess is well-backed as an add-on in stubborn cases. It is not a first-line treatment and never used alone.
Frequently asked questions
Is HBOT a replacement for surgery and antibiotics?
No. HBOT is always an add-on. Surgical drainage of the abscess and IV antibiotics are the base. HBOT is added when those have failed, when there are multiple abscesses, or when the patient has a higher-risk setting like immune suppression.
How long does a course take?
The standard course is 20 to 30 sessions, daily 5 days per week, running about 4 to 6 weeks. Some patients run shorter courses if they respond fast; others run longer if abscesses recur.
Which brain abscess cases respond best?
Stubborn cases that have failed standard care, patients with multiple abscesses, immunocompromised hosts, and pediatric patients. The Bartek 2016 cohort showed a clear reoperation drop with HBOT in adult cases of all types.
Will Medicare cover this?
Yes for stubborn cases or high-risk patients with proof of need. Cover is laid out in LCD L33532 and asks for infectious disease or neurosurgery sign-off.
Can a soft-shell wellness chamber treat this?
No. Brain abscess care asks for 2.0 to 2.4 ATA in a medical chamber. Soft-shell chambers reach only 1.3 ATA. That pressure is not enough to drive brain tissue oxygen to the level needed to restore white cell killing.
Sources
- Kurschel Pediatric Brain Abscess Study, 2006
- Bartek Acta Neurochirurgica Cohort, 2016
- Lambrechts StatPearls Intracranial Abscess, 2024
- PubMed HBOT Brain Abscess Review, 2018
- Systematic Review HBOT Brain Abscess, 2021
- Brouwer NEJM Brain Abscess Review, 2014
- UHMS Intracranial Abscess Chapter, current
- UHMS Journal Intracranial Abscess Paper, 2012
- PMC Brain Abscess HBOT Adjuvant Study, 2025
- UHMS 15th Edition Intracranial Abscess Update, 2024
- Tibbles and Edelsberg NEJM Review, 1996
- CMS NCD 20.29 Hyperbaric Oxygen Therapy, 2017
- CMS LCD L33532, 2025
Medical disclaimer
This page is medical journalism, not medical advice. Brain abscess and spinal abscess are serious conditions that ask for hospital-based care from neurosurgery and infectious disease teams. HBOT is one add-on in a layered plan. It does not replace surgical drainage or IV antibiotics. Talk to a hyperbaric medicine doctor and the treating team about care choices.